Chimeric Therapeutics Limited
CHMMFOTCHealthcare● Active
$0.10
+$0.00(+0.00%)
Market Cap$4104310
P/E Ratio—
52W High$0.1
52W Low$0.001
Chimeric Therapeutics Limited (CHMMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHMMF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 27, 2026EPS Actual
-$0.23
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 27, 2026
After Market Close
CHMMF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 28, 2026 | — | — | — | — | — | — |
| — Q1 FY2026 | Feb 27, 2026 | — | -$0.23 | — | — | — | — |
| — Q1 FY2025 | Feb 28, 2025 | — | -$0.00 | — | $0.00B | — | — |
| ▼ Q3 FY2024 | Aug 30, 2024 | -$0.02 | -$1.47 | -7600.1% | $-0.00B | — | — |
| ▲ Q1 FY2024 | Feb 27, 2024 | -$0.01 | $0.00 | +122.0% | $0.00B | — | — |
| ▼ Q3 FY2023 | Aug 31, 2023 | -$0.01 | -$2.14 | -16751.1% | $0.00B | — | — |
| ▲ Q1 FY2023 | Feb 28, 2023 | -$0.03 | -$0.02 | +31.2% | $0.00B | — | — |
| — Q3 FY2022 | Aug 30, 2022 | — | -$0.01 | — | $0.00B | — | — |
Q3 FY2026
Aug 28, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 27, 2026
EPS Actual
-$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 28, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 30, 2024Miss
EPS Actual
-$1.47
EPS Est.
-$0.02
EPS Surpr.
-7600.1%
Revenue
$-0.00B
Q1 FY2024
Feb 27, 2024Beat
EPS Actual
$0.00
EPS Est.
-$0.01
EPS Surpr.
+122.0%
Revenue
$0.00B
Q3 FY2023
Aug 31, 2023Miss
EPS Actual
-$2.14
EPS Est.
-$0.01
EPS Surpr.
-16751.1%
Revenue
$0.00B
Q1 FY2023
Feb 28, 2023Beat
EPS Actual
-$0.02
EPS Est.
-$0.03
EPS Surpr.
+31.2%
Revenue
$0.00B
Q3 FY2022
Aug 30, 2022
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 27, 2026 | — | $0.10 | $0.10 | +0.00% |
| — Q1 FY2025 | Feb 28, 2025 | — | $0.10 | $0.10 | +0.00% |
| ▼ Q3 FY2024 | Aug 30, 2024 | -7600.1% | $3.00 | $3.00 | +0.00% |
| ▲ Q1 FY2024 | Feb 27, 2024 | +122.0% | $3.00 | $3.00 | +0.00% |
| ▼ Q3 FY2023 | Aug 31, 2023 | -16751.1% | $1.25 | $1.25 | +0.00% |
| ▲ Q1 FY2023 | Feb 28, 2023 | +31.2% | $6.00 | $6.00 | +0.00% |
| — Q3 FY2022 | Aug 30, 2022 | — | No price data | $6.50 | — |
| — Q1 FY2022 | Feb 27, 2022 | — | No price data | $6.50 | — |
Q1 FY2026+0.00%
Report Date
Feb 27, 2026
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q1 FY2025+0.00%
Report Date
Feb 28, 2025
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q3 FY2024+0.00%
Report Date
Aug 30, 2024
EPS Beat/Miss
-7600.1%
Price Before
$3.00
Price After
$3.00
Q1 FY2024+0.00%
Report Date
Feb 27, 2024
EPS Beat/Miss
+122.0%
Price Before
$3.00
Price After
$3.00
Q3 FY2023+0.00%
Report Date
Aug 31, 2023
EPS Beat/Miss
-16751.1%
Price Before
$1.25
Price After
$1.25
Q1 FY2023+0.00%
Report Date
Feb 28, 2023
EPS Beat/Miss
+31.2%
Price Before
$6.00
Price After
$6.00
Q3 FY2022—
Report Date
Aug 30, 2022
EPS Beat/Miss
—
Price Before
—
Price After
$6.50
Q1 FY2022—
Report Date
Feb 27, 2022
EPS Beat/Miss
—
Price Before
—
Price After
$6.50
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHMMF ends December
Chimeric Therapeutics Limited (CHMMF) most recently reported earnings on February 27, 2026 for Q1 FY2026, posting EPS of $-0.23 (in line with the analyst consensus of —). The next CHMMF earnings date is expected around September 1, 2026.
Each quarter, investors track CHMMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHMMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHMMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHMMF earnings · 4 questionsChimeric Therapeutics Limited's next earnings report is expected around September 1, 2026. CHMMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHMMF historically reports after market close (AMC).
CHMMF earnings datewhen is CHMMF earningsCHMMF next earnings datewhen does CHMMF report earningsCHMMF earnings calendar
▸ Source: FMP · Chimeric Therapeutics Limited SEC filings · US GAAP · Chimeric Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026